$ETRM, Most Active Volume Stock: EnteroMedics Inc.

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
$ETRM,

Most Active Volume Stock: EnteroMedics Inc. (NASDAQ:ETRM)
By
Mindy Sparks -
December 9, 2016
stock-exchange-911605_1280-696x492.jpg

EnteroMedics Inc. (NASDAQ:ETRM) belonging to the Medical sector has surged 29.07% and closed its last trading session at $0.07.

The company reported its EPS on 11/07/2016. Currently, the stock has a 1 Year Price Target of $1.1.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.

EnteroMedics Inc. on 11/07/2016 reported its EPS as $-0.17 with the analysts projecting the EPS of the stock as $-0.5. The company beat the analyst EPS Estimate with the difference of $0.33. This shows a surprise factor of 66%.

Many analysts have provided their estimated foresights on EnteroMedics Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-0.5. Whereas they predicted High and Low Earnings Estimate as $-0.5 and $-0.5 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.95.

Analysts are also projecting an Average Revenue Estimate for EnteroMedics Inc. as $300 Million in the Current Quarter. This estimate is provided by 1 analysts. The High Revenue estimate is predicted as 300 Million, while the Low Revenue Estimate prediction stands at 300 Million. The company’s last year sales total was 149 Million.

The Company got Downgrade by ROTH Capital on 9-Jun-16 from Buy to Neutral.

Insider Trades for EnteroMedics Inc. show that the latest trade was made on 2 Jun 2016 where Delange (Peter M), the Officer completed a transaction type “Buy” in which 20000 shares were traded at a price of $0.55.

1 analysts projected Price Targets for EnteroMedics Inc.. The analysts believe that the company stock price could grow as high as $2. The Low Price target projection by analysts is $2 and the Mean Price Target is $2.

EnteroMedics Inc. (NASDAQ:ETRM) has the market capitalization of $7.82 Million. The company rocked its 52-Week High of $2.7 on Dec 31, 2015 and touched its 52-Week Low of $0.04 on Nov 22, 2016. The stock has Return on Assets (ROA) of -197.6 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of -568.7 percent.

The stock is currently showing YTD performance of -96.43 Percent. The company has Beta Value of 2.16 and ATR value of 0.02. The Weekly and Monthly Volatility stands at 22.31% and 29.56%.

Company profile:

EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Shaky Ground in Securities Fraud Suit

Updated Category News Views 128

Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...

Continue Reading
Doppel's Strategic Expansion: Adding PropRise Innovators

Updated Category News Views 62

Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...

Continue Reading
Johnsonville's Election Effort: Sausage for Dinner Gains Momentum

Updated Category News Views 88

Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...

Continue Reading
Silvercorp Updates El Domo Budget Amid Challenges

Updated Category News Views 141

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Continue Reading
Historic Surge: Women Veterans Join 120th Congress

Updated Category News Views 107

The Winds of Change Are Blowing Through Washington It looks like the face of Congress is getting a combat-ready makeover with the latest election results. Veterans are stepping up to the plate, claiming at least 79 seats in the 120th Congress, with a historic presence of women veterans making waves. Yeah, we're talking about 11 women veterans hitting the halls of power,...

Continue Reading
Life with PAH: A Journey of Awareness and Hope

Updated Category News Views 230

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Continue Reading
The Braff Group's 400th Health Care M&A Milestone

Updated Category News Views 31

No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...

Continue Reading
Citius Unveils Promising LYMPHIR Data at EORTC Conference

Updated Category News Views 77

A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...

Continue Reading
Webull Corp Caught in Legal Storm; Investors Take Note

Updated Category News Views 87

A Legal Storm Brewing It's like walking into a saloon, expecting a smooth drink, only to find a bar fight breaking out in front of you. That's the scene with Webull Corporation (NASDAQ: BULL) right now. This time, they ain't just shooting the breeze; they're in the line of legal fire. SBS Law, a heavyweight in shareholder rights, is rallying the troops for a class action...

Continue Reading
NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Updated Category News Views 34

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...

Continue Reading

Top 5 Most Recently Viewed Articles

Alex Bastian Named VP of Commercial Strategy at Memo Therapeutics

Updated Category News Views 282

Alex Bastian Appointed as VP of Commercial Strategy at Memo Therapeutics AG Memo Therapeutics AG (or “MTx”), a late-stage biotech firm committed to transforming unique human immune responses into effective treatments for viral infections and cancer, has announced the appointment of Alex Bastian as its new VP of Commercial Strategy. Expertise in the Biotech Industry...

Continue Reading
Understanding Alliant Energy's Rising Short Interest Insights

Updated Category News Views 282

Alliant Energy's Rising Short Interest Alliant Energy's short percent of float has recently increased, reaching 9.49% since the last report. The energy provider has reported a total of 7.74 million shares sold short. This accounts for about 3.46% of its total available shares for trading, indicating an active trading environment. Understanding Short Interest Short...

Continue Reading
China's 2024 Fiscal Revenue: A Shift Towards Proactive Measures

Updated Category News Views 270

China's Fiscal Revenue Growth and Economic Challenges In recent reports, it's shown that China's fiscal revenue in 2024 has seen an increase of 1.3% year on year. This rate of growth is a significant decline from the 6.4% expansion recorded in 2023. The slowdown in revenue has raised concerns amid economic uncertainties. The Impact of the Property Market One of the...

Continue Reading
Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health

Updated Category News Views 542

Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health In a significant step forward for youth mental health advocacy, Bill Brady, the CEO of Troomi Wireless, has been appointed to the Board of Directors of Speak Our Minds, a nonprofit organization dedicated to combatting the youth mental health crisis. This collaboration aims to unite technology with a...

Continue Reading
Investigation of Investors' Claims Against Unisys Corporation

Updated Category News Views 467

Rosen Law Firm Investigates Claims for Unisys Corporation Investors Rosen Law Firm, a well-respected global investor rights organization, is currently conducting an investigation concerning potential securities claims on behalf of shareholders of Unisys Corporation (NYSE: UIS). This investigation arises from serious allegations suggesting that Unisys might have provided...

Continue Reading